A Joint ACCC and Medscape Project

The goal of this educational initiative is to help clinicians better assess patients at risk for chemotherapy-induced nausea and vomiting (CINV), make sense of the various guidelines available for CINV, and learn how to apply these evidence-based guidelines for the prevention and management of CINV.

Faculty: Mark G. Kris, MD; Stephen A. Mayer, MD, PhD.

This activity is intended for oncologists, oncology nurses, and pharmacists.

• Physicians—maximum of 0.50 AMA PRA Category 1 Credit(s)™
• Nurses—0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)
• Pharmacists—0.50 Knowledge-based ACPE(0.050 CEUs)

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an independent educational grant from Eisai.

The goal of this activity is to provide expert perspective and guidance on strategies for improving awareness and implementation of new evidence-based practices and agents and for individualizing treatment of patients with newly diagnosed multiple myeloma.

Faculty: Paul G. Richardson, MD; William I. Bensinger, MD; Sagar Lonial, MD; John G. Krikorian, MD.

This activity is intended for clinicians who specifically care for patients with multiple myeloma.

• Physicians — maximum of 1.00 AMA PRA Category 1 Credit(s)™

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an independent educational grants from Allos Therapeutics, Seattle Genetics, Genentech and Biogen Idec.

The goal of this activity is to communicate both the scientific updates from leading non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) experts and practical perspectives of leading community hematologists/oncologists.

Faculty: James O. Armitage, MD; Anas Younes, MD; Julie M. Vose, MD, MBA; Susan M. O'Brien, MD.

This activity is intended for clinicians who treat patients with lymphoma and leukemia.

• Physicians — maximum of 0.50 AMA PRA Category 1 Credit(s)™
• Nurses — 0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an independent educational grants from Allos Therapeutics, Seattle Genetics, Genentech and Biogen Idec.

The goal of this activity is to review key issues facing clinicians who care for patients with advanced prostate cancer and discuss how best to incorporate available treatment strategies for advanced prostate cancer into the clinic using a case-study approach

Faculty: A. Oliver Sartor, MD; Sandra M. Kelly, MS, RN, NP.

This activity is intended for nurses and nurse practitioners caring for patients with prostate cancer.

• Nurses —0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an educational grant from sanofi-aventis US.

The goal of this activity is to provide a basic foundation for increasing awareness and understanding of the importance of individualizing the treatment of patients with newly diagnosed multiple myeloma.

Faculty: Sagar Lonial, MD.

This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with multiple myeloma.

• Physicians—maximum of 0.50 AMA PRA Category 1 Credit(s)™

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an independent educational grant from Millennium: The Takeda Oncology Company

Supported by an educational grant from Celgene.

The goal of this activity is to examine, through the presentation of patients in a clinical context, the many issues, including front-line treatment options and patient characteristics, involved in choosing an appropriate therapy for patients newly diagnosed with multiple myeloma.

Faculty: G. David Roodman, MD.

This activity is intended for hematologists, oncologists, and other healthcare professionals who treat patients with multiple myeloma.

• Physicians—maximum of 0.75 AMA PRA Category 1 Credit(s)™

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an independent educational grant from Millennium: The Takeda Oncology Company

Supported by an educational grant from Celgene.

The goal of this activity is to discuss and synthesize the latest data on front-line salvage therapies for patients with NHL. The activity provides an overview of 4 different disease subtypes of NHL in which transplantation is an option for treatment.

Faculty: Ginna G. Laport, MD, Ajay Gopal, MD, Philippe Armand, MD, PhD, Julie M Vose, MD.

This activity is intended for hematologists, oncologists, hematologic transplant physicians, and other healthcare professionals who treat patients with non-Hodgkin lymphoma (NHL).

• Physicians—maximum of 3.00 AMA PRA Category 1 Credit(s)™

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and the National Marrow Donor Program. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

This activity is intended for oncologists, oncology nurses, and all other healthcare providers who care for patients with advanced non-small cell lung cancer (NSCLC).

Faculty: Jeffrey Crawford, MD; Lee S. Schwartzberg, MD; Nicholas Thatcher, MD, PhD; Maureen F. Zakowski, MD.

This activity is to discuss the changing treatment paradigm for advanced NSCLC, with a focus on the use of tumor histology and molecular profiling in guiding treatment selection in both the first-line and maintenance setting.

• Physicians—maximum of 2.00 AMA PRA Category 1 Credit(s)™

Supported by an independent educational grant from Lilly.

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

This activity is designed to help clinicians distill and appropriately incorporate newly presented data from the 14th World Conference on Lung Cancer into their practice and better manage their patients with advanced NSCLC.

Faculty: Hossein Borghaei, DO; Joan H. Schiller, MD; Mark Socinski, MD; Giorgio V. Scagliotti, MD, PhD.

This activity is intended for oncologists, oncology nurses, and all other healthcare professionals who manage and treat patients with advanced non-small cell lung cancer (NSCLC).

• Physicians—maximum of 0.50 AMA PRA Category 1 Credit(s)™
• Nurses—0.50 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

Supported by an educational grant from Pfizer, Boehringer Ingelheim, Genentech, and Lilly.

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

This activity will explore roles and communication touch points for primary care providers (PCPs) and hematologists/oncologists in managing patients with hematologic cancer, identify strategies and tools for optimal care, and discuss cancer survivorship recommendations.

Faculty: Kevin Oeffinger, MD, Jonathan Marsh, MD, Larissa Nekhlyudov, MD, Kanti R. Rai, MD.

This activity is intended for hematologists, oncologists, primary care providers, nurses, social workers, and pharmacists.

• Physicians—maximum of 1.00 AMA PRA Category 1 Credit(s)™
• Nurses—1.00 CBRN Contact Hour(s)
• Pharmacists—1.00 knowledge-based ACPE (0.100 CEUs)
• Social Workers—1.00 CE clock hour(s)

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an independent educational grant from Leukemia and Lymphoma Society.

The annual meeting of the American Society of Clinical Oncology is both exciting and overwhelming. Whether you were fortunate enough to attend in person this year or had to skip it, the sheer volume of new data can make it difficult to identify findings that will be most clinically impactful for practitioners.

To help you stay up–to–date with key presentations from Chicago, the ACCC is pleased to bring you "First Responses," succinct video summaries and community perspectives by experts in breast cancer (in partnership with Medscape Oncology), lung cancer (in partnership with Medscape Oncology and Fox Chase Cancer Center), and lymphoma.

Click below to access these free continuing education activities.

Breast Cancer Highlights From Chicago: Expert and Community Perspectives

A First Response on the Advances in Non-Small Cell Lung Cancer

First Response on Lymphoma

Triple–Negative Metastatic Breast Cancer: Current Data and Clinical Practice

The goal of this activity is to synthesize the latest understanding of the epidemiology, clinicopathology, and patterns of recurrence associated with triple–negative breast cancer as well as to discuss current and emerging treatment approaches for patients with advanced disease.

Faculty: Erica L. Mayer, MD, MPH; Nancy U. Lin, MD.

This activity is intended for oncologists, oncology nurses, pathologists, and other healthcare practitioners who care for and/or treat women with triple-negative metastatic breast cancer.

• Physicians—maximum of 0.75 AMA PRA Category 1 Credit(s)™
• Nurses—0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by educational grants from Genentech BioOncology and sanofi-aventis US.

Non–Hodgkin Lymphoma Forum: Addressing the Challenges in Community Practice

The goal of this activity is to address the clinical challenges facing clinicians in the community practice.

Faculty: Myron S. Czuczman, MD; Fredrick B. Hagemeister, MD; Morie A. Gertz, MD; Oscar Ballester, MD.

This activity is intended for hematologists, medical oncologists, oncology nurses, and other healthcare professionals involved in the diagnosis and treatment of patients with non-Hodgkin Lymphoma.

• Physicians—maximum of 0.75 AMA PRA Category 1 Credit(s)™
• Nurses—0.75 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

Learn more at
Community Clinical Perspectives: A Joint ACCC and Medscape Project.

Supported by an independent educational grant from Millennium: The Takeda Oncology Company.

Metastatic Breast Cancer Clinic: A Case–based Curriculum

This is a collection of activities about metastatic breast cancer that will improve knowledge, confidence, and practice patterns among community practitioners, with a focus on special treatment challenges, use of intrinsic tumor subtypes to guide treatment, and maintaining and improving quality of life for women with breast cancer throughout the duration of their treatment for advanced disease.

Faculty: Harold J. Burnstein, MD, PhD, Clifford Hudis, MD, and Lisa A. Carey, MD.

This activity is intended for physicians and nurses.

• Physicians—maximum of 2.5 AMA PRA Category 1 Credit(s)™
• Nurses—up to 1.75 ANCC Contact Hour(s)
• Nurses will be issued a letter of completion for the balance of credits.

Follow the links below for this program.

• Curriculum Page
• Curriculum introduction by Dr. Burstein
• Self Assessment
• Metastatic Breast Cancer: Striking the Right Balance
• The Biology of Breast Cancer
• Case Submission Form
• Webcast: Relapsed Metastatic Breast Cancer With CNS Involvement
• Webcast: Evolving Lines of Treatment for Recurrent Metastatic Breast Cancer

  

Supported by an educational grant from sanofi-aventis US and Genentech.

Optimizing the Use of Aromatase Inhibitors in Breast Cancer—Issue 3

Learn the most up–to–date data on endocrine therapy and the key issues involved in its optimal use for patients with breast cancer. This CME/CE activity is intended for oncologists, oncology nurses, pharmacists, primary care practitioners, obstetricians/gynecologists, and other healthcare professionals who treat patients with breast cancer.

Click here to view the program online.

Faculty: Ruth O'Regan, MD; Joseph J. Merchant, MD; Harold J. Burstein, MD, PhD.

• Physicians—maximum of 1.00 AMA PRA Category 1 Credit(s)™
• Nurses—1.00 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)
• Pharmacists—1.00 knowledge-based ACPE (0.100 CEUs)
• All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.

Supported by an independent educational grant from Pfizer.